IL17A and liver disorder: Also, five proteins (HSP90B1, Protein S100-A9 [S100A9], MMP1, matrix metalloproteinase-9 [MMP9], and CSF3) in the IL17 signaling pathway are in phase III clinical trials for treating solid tumors and have the potential to treat liver diseases (Fig. 5E and supplemental Table S15).